Leflunomide-induced Toxic Epidermal Necrolysis in a Patient with Rheumatoid Arthritis
Journal of Rheumatic Diseases
;
: 326-330, 2014.
Artigo
em Inglês
| WPRIM
| ID: wpr-54157
ABSTRACT
Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998 and has been available in Korea since 2003. Allergic cutaneous reactions (rash, purpura) are common (<10%) side effects of leflunomide, but severe cases such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) are rarely reported. There has not been a report of SJS or TEN induced by leflunomide in Korea. Here we report a case of leflunomide-induced TEN in a patient with rheumatoid arthritis. Leflunomide was discontinued, and the TEN was treated with methylprednisolone, cholestyramine and immunoglobulin. The skin lesion eventually resolved over four weeks with residual post-inflammatory hyperpigmentation.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Artrite Reumatoide
/
Pele
/
Imunoglobulinas
/
Metilprednisolona
/
Resina de Colestiramina
/
Síndrome de Stevens-Johnson
/
Hiperpigmentação
/
Coreia (Geográfico)
Limite:
Humanos
País/Região como assunto:
Ásia
Idioma:
Inglês
Revista:
Journal of Rheumatic Diseases
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS